WeTrials
WeTrials is an AI-powered digital health platform that simplifies clinical trial discovery and enrollment for cancer patients and caregivers, particularly in brain, breast, lung, pediatric, and prostate cancers, through institutional partnerships with advocacy groups and research consortia.
- Company typePrivate
- Founded2021
- HeadquartersMechanicsburg, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingSoftware
What WeTrials does
WeTrials is an AI-powered digital health platform that simplifies the clinical trial journey for individuals diagnosed with cancer and their care partners. Founded in 2022 and headquartered in Mechanicsburg, Pennsylvania (with operating presence in Philadelphia), the company addresses the difficulty patients face in discovering, evaluating, and understanding cancer clinical trials. Its primary focus is on brain cancer, breast cancer, lung cancer, pediatric cancer, and prostate cancer. The platform centralizes clinical trial information, uses AI to translate complex trial language into accessible explanations, and delivers personalized trial matching based on patient diagnosis and preferences.
The core product is the WeTrials AI Patient Engagement Platform, supplemented by iOS and Android mobile applications, a Learning Center with condition-specific educational content, The Caregiver Chronicles video podcast series, free checklists and guides, and a beta WeTrials AI Assistant for conversational patient support. Technology features include generative AI for patient Q&A and language simplification, a recommendation engine for trial matching, knowledge retrieval tied to molecular diagnostics, and process automation for enrollment workflows. A technically notable integration embeds WeTrials trial links directly within GenomOncology's GO Genomic Reports, enabling a workflow from Belay Diagnostics' Summit 2.0 liquid biopsy output through to trial enrollment for CNS cancer patients.
The business model is free to consumers; revenue is generated through institutional partnerships. Named partners include Beat Childhood Cancer at Penn State College of Medicine (a 50+ hospital pediatric research consortium spanning North America, South America, and Europe), the American Brain Tumor Association (white-labeled Clinical Trial Finder on the ABTA website), GenomOncology and Belay Diagnostics (genomic report integration), the Glioblastoma Support Network (co-founders sit on the GSN board), and the Canadian Cancer Society (joint webinar work). WeTrials operates under HIPAA and CCPA compliance. The company is led by co-founders Romeo De Leon (CEO) and Dr. Alireza Mansouri, MD (CMO, named Penn State Health Physician of the Year in 2025), with a small team of software, product, clinical research, and digital marketing staff.
WeTrials firmographics
Firmographics- Name
- WeTrials
- Legal name
- WeTrials
- Website
- https://wetrials.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- WeTrials is an AI-powered digital health platform that simplifies clinical trial discovery and enrollment for cancer patients and caregivers, particularly in brain, breast, lung, pediatric, and prostate cancers, through institutional partnerships with advocacy groups and research consortia.
- Ownership category
- akta.pro rank
WeTrials industry classification
Industry- Product category
- Clinical Trial Patient Engagement Platform
- NAICS
- Computer Systems Design and Related Services (54151), Web Search Portals, Libraries, Archives, and Other Information Services (519), Professional, Scientific, and Technical Services (54)
- SIC
- Services-Health Services (8000)
- akta.pro industry
- eConsent & Patient Engagement at SiteHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality ManagementHealthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
Keywords
Where WeTrials is headquartered
LocationHeadquarters
- HQ city
- Mechanicsburg
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
WeTrials business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Platform Services to Healthcare Institutions: WeTrials provides its AI-powered patient engagement platform to healthcare institutions, research consortia, and advocacy organizations. The platform appears to be offered at no cost to patients while generating revenue through partnerships with healthcare organizations, clinical trial sponsors, and research institutions.
- Institutional Partnerships: Revenue generated through partnerships with institutions, advocacy groups, and healthcare organizations that use WeTrials to connect patients with clinical trials. Services include technology access, tools, resources, and support for patient engagement.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
WeTrials product offering
Product offeringCore offering
WeTrials operates an AI-powered patient engagement platform that helps cancer patients and caregivers discover, understand, and navigate clinical trial opportunities. The platform centralizes study information across brain, breast, lung, pediatric, and prostate cancers, translates complex trial language into understandable terms, and provides personalized trial matching, educational content, and support resources. It is offered free to patients and is distributed through white-label embedded integrations with advocacy groups, genomic diagnostic reports, and research consortia.
Product overview
WeTrials is a clinical trial patient engagement platform consisting of a core AI-powered patient engagement platform and multiple integrated modules. The core WeTrials AI Patient Engagement Platform provides simplified trial discovery, AI-powered matching, and personalized support. Supporting products include the ABTA Clinical Trial Finder (white-labeled discovery tool), WeTrials Learning Center (educational content), The Caregiver Chronicles (video series), Checklists & Guides (patient resources), Mobile App (iOS/Android), WeTrials AI Assistant (beta chatbot), and specialized tools for Clinicians and Advocacy Groups. The platform targets multiple cancer types: brain cancer, breast cancer, lung cancer, pediatric cancer, and prostate cancer.
Differentiator
Problem solved
Functional benefit
Products and services
- WeTrials AI Patient Engagement Platform AI-powered platform that helps cancer patients and families discover, understand, and navigate clinical trial opportunities. Centralizes study information, provides simplified trial language, and offers personalized educational and support resources across brain, breast, lung, pediatric, and prostate cancers. Distributed to patients free of charge and licensed to healthcare institutions and research consortia.
- ABTA Clinical Trial Finder White-labeled clinical trial discovery tool powered by WeTrials and embedded on the American Brain Tumor Association website. Provides brain tumor patients and families with intuitive trial summaries, advanced filtering, and streamlined navigation to find relevant clinical trials.
- WeTrials Mobile App
Companies that use WeTrials
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
WeTrials technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
WeTrials partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Beat Childhood Cancer at Penn State College of MedicinecoreBeat Childhood Cancer, an international pediatric cancer research consortium with 50+ hospitals and research institutions across North America, South America, and Europe, has implemented the WeTrials AI-powered patient engagement platform. Families can access simplified study information, personalized educational experiences, and AI-powered engagement tools to discover and navigate pediatric cancer clinical trials.
- GenomOncologycoreStrategic partnership with GenomOncology to help CNS cancer patients access and enroll in clinical trials faster. The collaboration embeds a direct link to WeTrials' platform within GenomOncology's GO Genomic Reports, creating a seamless pathway from molecular diagnosis to trial enrollment. Initial focus on CNS cancer patients tested through Belay Diagnostics, with plans to expand to additional diagnostic partners and cancer types.
- Belay DiagnosticscorePartnership expands on existing GenomOncology-Belay Diagnostics relationship. Belay's Summit 2.0 liquid biopsy test workflow integrates with GenomOncology's GO Pathology Workbench, and the GO Genomic Report now includes direct link to WeTrials platform. This creates integrated pathway from molecular diagnosis to trial enrollment for CNS cancer patients.
- American Brain Tumor Association (ABTA)corePartnership to advance clinical trial accessibility for brain tumor patients. WeTrials launched the ABTA Clinical Trial Finder—a patient-centered tool live on the ABTA website that helps patients and families explore clinical trials with simplified summaries, advanced filtering, and intuitive navigation. Combined ABTA's community roots with WeTrials' technology platform.
- Glioblastoma Support NetworkcoreWeTrials co-founders Dr. Alireza Mansouri and Romeo De Leon joined the GSN board as Directors. Partnership aims to enhance support, resources, and hope for individuals and families impacted by glioblastoma. Combines WeTrials' expertise in clinical trials with GSN's patient support framework.
- Canadian Cancer SocietyminorCollaborated with Canadian Cancer Society to host webinar 'Demystifying Clinical Trials for Indigenous People' presented by Dr. Alireza Mansouri. Webinar focused on empowering Indigenous communities with knowledge about clinical trials for brain tumors and glioblastoma.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
WeTrials competitors and assessment
Company assessmentDirect peers
- Deep 6 AI: AI-native clinical trial matching platform that uses EHR and structured patient data to accelerate enrollment. Closest direct competitor to WeTrials' core AI trial-matching thesis, though focused on site/sponsor workflows rather than direct-to-patient engagement.
- Mendel: AI platform for matching patients to clinical trials from unstructured medical records, primarily serving sponsors and CROs. Comparable to WeTrials' AI matching layer but with a B2B-first commercial model and a broader therapeutic scope.
- Antidote (formerly TrialReach): Patient-facing clinical trial matching platform that partners with patient advocacy groups and pharma sponsors. Most analogous business model to WeTrials' advocacy-embedded, patient-first approach.
- Massive Bio: AI-driven oncology clinical trial enrollment company that pre-screens cancer patients against trial criteria. Directly comparable to WeTrials in the oncology niche and in the use of AI for patient-trial matching.
- TrialX: Digital health platform offering AI-powered clinical trial matching and patient recruitment, with both consumer and provider-facing surfaces. Comparable in functionality and target users to WeTrials' platform.
- xCures: AI platform that matches cancer patients to treatment options including clinical trials, with deep oncology focus. Closest peer to WeTrials in terms of cancer-specific AI matching and patient engagement.
- Clara Health: Patient-centric clinical trial matching service that combines AI tools with human navigators, partnering with advocacy organizations. Highly comparable to WeTrials' patient-first, advocacy-embedded model.
Broad incumbents
- Medidata (Dassault Systèmes): Large, established clinical trial technology platform (EDC, CTMS, eCOA, RTSM). Represents the enterprise incumbent whose broader portfolio can absorb and bundle trial-matching functionality, competing indirectly with WeTrials at the sponsor level.
- IQVIA: Global CRO and life sciences technology provider with extensive clinical trial matching and patient recruitment capabilities. Competes with WeTrials indirectly at the pharma-sponsor layer with vastly greater scale and data assets.
Emerging players
- Castlight Health: Health navigation platform historically focused on guiding employees to care options; adjacent to WeTrials' patient-navigation thesis and could expand into clinical trial discovery as a feature.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
WeTrials social profiles
Digital presenceWeTrials compliance and trust
Trust signalCompliance2 records
WeTrials financial estimates
Financial estimateRevenue estimate
Valuation estimate
WeTrials leadership team
Management profileNumber of profiles
Profiles4 records
WeTrials funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WeTrials M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WeTrials
What does WeTrials do?
WeTrials operates an AI-powered patient engagement platform that helps cancer patients and caregivers discover, understand, and navigate clinical trial opportunities. The platform centralizes study information across brain, breast, lung, pediatric, and prostate cancers, translates complex trial language into understandable terms, and provides personalized trial matching, educational content, and support resources. It is offered free to patients and is distributed through white-label embedded integrations with advocacy groups, genomic diagnostic reports, and research consortia.
Is WeTrials a public or private company?
WeTrials is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was WeTrials founded?
WeTrials was founded in 2021. It employs 1 to 10 people.
Where is WeTrials based?
WeTrials is headquartered in Mechanicsburg, United States, in the North America region.
How does WeTrials make money?
Two revenue lines are on record. Platform Services to Healthcare Institutions are the primary driver. The others are institutional Partnerships.
Who are WeTrials's main competitors?
Direct peers on record are Deep 6 AI, Mendel, Antidote (formerly TrialReach), Massive Bio, TrialX, xCures and Clara Health. Broad incumbents are Medidata (Dassault Systèmes) and IQVIA. Castlight Health is listed as an emerging player.
Does WeTrials have an API?
No public API is recorded for WeTrials.
What industry is WeTrials in?
WeTrials's product category is Clinical Trial Patient Engagement Platform. Its primary akta.pro industry code is HLAGACAI, eConsent & Patient Engagement at Site, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 54151 and its SIC code is 8000.